Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Chinese Patent Office
McKinsey
Harvard Business School
Novartis
US Department of Justice
Accenture
Moodys
Healthtrust
Fuji

Generated: January 20, 2018

DrugPatentWatch Database Preview

SODIUM SULFACETAMIDE Drug Profile

« Back to Dashboard

Which patents cover Sodium Sulfacetamide, and what generic alternatives are available?

Sodium Sulfacetamide is a drug marketed by Akorn and Sola Barnes Hind and is included in five NDAs.

The generic ingredient in SODIUM SULFACETAMIDE is sulfacetamide sodium. There are three drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the sulfacetamide sodium profile page.
Drug patent expirations by year for SODIUM SULFACETAMIDE
Medical Subject Heading (MeSH) Categories for SODIUM SULFACETAMIDE

US Patents and Regulatory Information for SODIUM SULFACETAMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 083021-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sola Barnes Hind SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 084147-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sola Barnes Hind SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 084143-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Akorn SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 083021-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Akorn SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 083021-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sola Barnes Hind SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 084146-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sola Barnes Hind SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 084145-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Chubb
Accenture
Teva
Federal Trade Commission
Medtronic
Deloitte
Queensland Health
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot